Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
Summary
Third Opinion Trial Synopsis:
Scientists are conducting a study to see if a medicine called ixazomib can help people with a type of cancer called multiple myeloma. They want to see if ixazomib alone or in combination with another medicine called lenalidomide can help patients who have already responded well to initial treatment with two other medicines. The goal of the study is to find out if ixazomib can be used as a maintenance therapy to help patients stay in remission.
Scientists are conducting a study to see if a medicine called ixazomib can help people with a type of cancer called multiple myeloma. They want to see if ixazomib alone or in combination with another medicine called lenalidomide can help patients who have already responded well to initial treatment with two other medicines. The goal of the study is to find out if ixazomib can be used as a maintenance therapy to help patients stay in remission.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a randomized, Phase 2 study involving two arms evaluating the efficacy and safety of ixazomib alone and the combination of both ixazomib and lenalidomide as maintenance therapy for patients with multiple myeloma who have achieved at least partial response (PR) or better after receiving a bortezomib- and lenalidomide-containing combination front-line therapy.
This is a randomized, Phase 2 study involving two arms evaluating the efficacy and safety of ixazomib alone and the combination of both ixazomib and lenalidomide as maintenance therapy for patients with multiple myeloma who have achieved at least partial response (PR) or better after receiving a bortezomib- and lenalidomide-containing combination front-line therapy.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: